Analysts Set Sartorius AG (FRA:SRT3) Price Target at €145.94

Sartorius AG (FRA:SRT3) has received an average recommendation of “Sell” from the nine analysts that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is €145.94 ($169.70).

SRT3 has been the topic of several recent research reports. Nord/LB set a €125.00 ($145.35) price target on Sartorius and gave the stock a “sell” rating in a research report on Monday, July 22nd. Deutsche Bank set a €170.00 ($197.67) price target on Sartorius and gave the stock a “neutral” rating in a research report on Monday, July 22nd. HSBC set a €150.00 ($174.42) price target on Sartorius and gave the stock a “neutral” rating in a research report on Friday, July 12th. Kepler Capital Markets set a €128.00 ($148.84) price target on Sartorius and gave the stock a “sell” rating in a research report on Tuesday, June 11th. Finally, UBS Group set a €184.00 ($213.95) price target on Sartorius and gave the stock a “neutral” rating in a research report on Friday, July 19th.

Sartorius stock traded up €6.20 ($7.21) during midday trading on Wednesday, hitting €178.40 ($207.44). 60,043 shares of the company were exchanged. The company’s fifty day moving average price is €181.64 and its 200-day moving average price is €163.78. Sartorius has a fifty-two week low of €71.00 ($82.56) and a fifty-two week high of €124.70 ($145.00).

About Sartorius

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Read More: Put Option

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.